Skip to search formSkip to main contentSkip to account menu

sotrastaurin

An orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

AEB071
NCIt Antineoplastic Agent TerminologySotrastaurin Acetate

Broader (2)

PyrrolesQuinazolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Sotrastaurin (AEB071) Alone and in Combination With Cyclosporine A Prolongs Survival Times of Non-Human Primate Recipients of Life-Supporting Kidney Allografts
Background. Sotrastaurin (STN), a novel oral protein kinase C inhibitor that inhibits early T-cell activation, was assessed in… 
2011
2011
Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis.
Protein kinase C (PKC) isotypes have emerged as key targets for the blockade of early T-cell activation. Herein, we report on the… 
2011
2011
Pharmacokinetics of Sotrastaurin Combined With Tacrolimus or Mycophenolic Acid in De Novo Kidney Transplant Recipients
Background. Sotrastaurin is a protein kinase C inhibitor in the development for prevention of organ rejection after renal… 
Review
2011
Review
2011
Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation
Importance of the field: The prevalence of acute renal allograft rejection has decreased substantially in past decades due to new… 
2010
2010
Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720
NVP‐AEB071 (AEB, sotrastaurin), an oral inhibitor of protein kinase C (PKC), effectively blocks T‐cell activation. The… 
Review
2010
Review
2010
Overview of sotrastaurin clinical pharmacokinetics.
Sotrastaurin (AEB071) is an investigational immunosuppressant that blocks T-lymphocyte activation through protein kinase C… 
2010
2010
Sotrastaurin and Tacrolimus Coadministration: Effects on Pharmacokinetics and Biomarker Responses
Sotrastaurin is an immunosuppressant that inhibits protein kinase C. In the prevention of acute rejection in organ… 
2010
2010
Sotrastaurin and cyclosporine drug interaction study in healthy subjects
Introduction. Sotrastaurin is an immunosuppressant that inhibits protein kinase C and blocks T‐lymphocyte activation. The authors… 
Review
2009
Review
2009
Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.
Blocking T-cell activation has a central role in the control of inflammatory diseases and in the prevention of graft rejection… 
2009
2009
The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.
AIMS Sotrastaurin is an immunosuppressant that reduces T-lymphocyte activation via protein kinase C inhibition. The effect of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)